Athersys, Inc, a biotechnology company, focuses on the research and development activities in the field of regenerative medicine. Its clinical development programs are focused on treating neurological conditions, cardiovascular diseases, inflammatory and immune disorders, and pulmonary and other conditions. The company's lead platform product includes MultiStem cell therapy, an allogeneic stem cell product, which is Phase III clinical study for the treatment of patients suffering from neurological damage from an ischemic stroke; and that is in Phase II clinical study for the treatment of patients with acute myocardial infarction, as well as that has completed Phase I clinical study for the treatment of patients suffering from leukemia or various other blood-borne cancers.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone216-431-9900
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$24.29 million
Profitability
Miscellaneous
Employees75
Next Earnings Date11/5/2019 (Estimated)
OptionableOptionable
Athersys (NASDAQ:ATHX) Frequently Asked Questions
What is Athersys' stock symbol?
Athersys trades on the NASDAQ under the ticker symbol "ATHX."
How were Athersys' earnings last quarter?
Athersys, Inc. (NASDAQ:ATHX) announced its quarterly earnings results on Wednesday, August, 7th. The biopharmaceutical company reported ($0.06) EPS for the quarter, beating the Zacks' consensus estimate of ($0.09) by $0.03. The biopharmaceutical company had revenue of $4.26 million for the quarter. Athersys had a negative return on equity of 106.93% and a negative net margin of 458.03%. View Athersys' Earnings History.
When is Athersys' next earnings date?
What price target have analysts set for ATHX?
1 brokerages have issued twelve-month price objectives for Athersys' stock. Their forecasts range from $8.00 to $8.00. On average, they expect Athersys' share price to reach $8.00 in the next year. This suggests a possible upside of 529.9% from the stock's current price. View Analyst Price Targets for Athersys.
What is the consensus analysts' recommendation for Athersys?
1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Athersys in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Athersys.
What are Wall Street analysts saying about Athersys stock?
Here are some recent quotes from research analysts about Athersys stock:
- 1. Maxim Group analysts commented, "Athersys reported 1Q19 with revenue of $1.4M (license fees, grants, and collaborative revenue), and a net loss of ($13M). The company ended 1Q19 with $51M in cash on the balance sheet. We note that expenses are rising as the MultiStem programs expand. Athersys should have runway into 2020." (5/9/2019)
- 2. According to Zacks Investment Research, "Athersys, Inc., a late stage biotechnology company, focuses on the research and development activities in the field of regenerative medicine. Its clinical development programs are focused primarily on treating critical care indications neurological conditions, cardiovascular diseases, inflammatory and immune disorders, pulmonary and other conditions. The company's lead platform product is MultiStem cell therapy, an off the shelf allogeneic stem cell product currently in Phase 3 clinical development for treating ischemic stroke. Based on promising Phase 2 results, this program has received Fast Track and RMAT (equivalent to Breakthrough Therapy for regenerative medicine treatments) designations from the FDA, as well as similar designations in Japan. The company also has an ongoing Phase II clinical study for treating patients with acute myocardial infarction; a planned Phase II for trauma (supported by the DOD). " (3/19/2019)
Has Athersys been receiving favorable news coverage?
News stories about ATHX stock have trended positive on Saturday, InfoTrie Sentiment reports. InfoTrie identifies negative and positive press coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Athersys earned a news sentiment score of 2.5 on InfoTrie's scale. They also gave media coverage about the biopharmaceutical company a news buzz of 6.0 out of 10, indicating that recent press coverage is somewhat likely to have an impact on the stock's share price in the near future. View News Stories for Athersys.
Who are some of Athersys' key competitors?
Some companies that are related to Athersys include ZIOPHARM Oncology (ZIOP), Amneal Pharmaceuticals (AMRX), Akero Therapeutics (AKRO), ANI Pharmaceuticals (ANIP), Arvinas (ARVN), Eagle Pharmaceuticals (EGRX), OrganiGram (OGI), Homology Medicines (FIXX), Alder Biopharmaceuticals (ALDR), Vanda Pharmaceuticals (VNDA), CannTrust (CNTTF), Kura Oncology (KURA), Cytokinetics (CYTK), MacroGenics (MGNX) and Rhythm Pharmaceuticals (RYTM).
What other stocks do shareholders of Athersys own?
Who are Athersys' key executives?
Athersys' management team includes the folowing people:
- Dr. Gil Van Bokkelen, Co-Founder, Chairman & CEO (Age 58)
- Mr. William B. J. Lehmann Jr., M.B.A., J.D., MBA, Pres, COO & Sec. (Age 53)
- Dr. John J. Harrington, Co-Founder, Chief Scientific Officer, Exec. VP & Director (Age 52)
- Ms. Laura K. Campbell, Sr. VP of Fin. (Age 55)
- Karen Hunady, Director of Corp. Communications & Investor Relations
Who are Athersys' major shareholders?
Athersys' stock is owned by many different of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (6.42%), Vanguard Group Inc. (4.14%), Prudential PLC (2.77%), Renaissance Technologies LLC (0.67%), Coastal Investment Advisors Inc. (0.27%) and Bank of New York Mellon Corp (0.24%). Company insiders that own Athersys stock include John J Harrington, Laura K Campbell and William Lehmann Jr. View Institutional Ownership Trends for Athersys.
Which institutional investors are selling Athersys stock?
ATHX stock was sold by a variety of institutional investors in the last quarter, including Allred Capital Management LLC, Alps Advisors Inc., Morgan Stanley and JPMorgan Chase & Co.. Company insiders that have sold Athersys company stock in the last year include John J Harrington and William Lehmann Jr. View Insider Buying and Selling for Athersys.
Which institutional investors are buying Athersys stock?
ATHX stock was purchased by a variety of institutional investors in the last quarter, including BlackRock Inc., Renaissance Technologies LLC, Vanguard Group Inc., Acadian Asset Management LLC, Coastal Investment Advisors Inc., Charles Schwab Investment Management Inc., Jane Street Group LLC and Wells Fargo & Company MN. View Insider Buying and Selling for Athersys.
How do I buy shares of Athersys?
Shares of ATHX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Athersys' stock price today?
One share of ATHX stock can currently be purchased for approximately $1.27.
How big of a company is Athersys?
What is Athersys' official website?
How can I contact Athersys?
Athersys' mailing address is 3201 CARNEGIE AVENUE, CLEVELAND OH, 44115. The biopharmaceutical company can be reached via phone at 216-431-9900 or via email at [email protected]
MarketBeat Community Rating for Athersys (NASDAQ ATHX)
MarketBeat's community ratings are surveys of what our community members think about Athersys and other stocks. Vote "Outperform" if you believe ATHX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ATHX will underperform the S&P 500 over the long term. You may vote once every thirty days.
